Table 2.
Primary Tumor Growth and Metastatic Features after Orthotopic Implantation of Human NSCLC Cell Lines in KSN Mice.
| Tumor | Days after implantation | Number of animals | Primary tumor | Tumor volume (mm3, Mean±SD) | Metastasis | |||
| Intrapulmonary | MLN | ALN | Others* | |||||
| PC-14 | 35 | 8 | 7/8 | 70.76±61.93 | - | 7/8 | 7/8 | LV, HLN, CW |
| A549 | 56 | 4 | 4/4 | 56.06±24.84 | 4/4(28.3±16.9)† | - | - | - |
| Lu-99 | 56 | 5 | 4/5 | 49.33±33.40 | - | 4/5 | 3/5 | LV, HLN, CW |
PC-14, Lu-99 and A549 cells were implanted into the lung parenchyma (1x106 cells/0.02 ml with 20 µg of Matrigel). Mice were sacrificed on the indicated days after tumor implantation, and the primary tumor volumes and the incidences of primary tumor and metastasis formation were determined as described in Materials and Methods section.
*
Abbreviations represent the different metastatic sites: MLN, mediastinal lymph node; ALN, axillary lymph node; LV, lumbar vertebrae; HLN, hilus lymph node of the lung; CW, chest wall.
†
Numbers in parentheses represent the mean number of tumor nodules on the lung surface±SD.